---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-297901"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2021-10-13T23:59:59+00:00"
generated_at: "2026-06-28T21:02:19.662988+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Catalyst Biosciences CFO Clinton Musil resigns; controller Seline Miller named interim CFO

## Summary
- Clinton Musil resigns as CFO effective Oct 29, 2021 for personal reasons; will provide consulting services.
- Seline Miller promoted to SVP Finance and named interim CFO and principal accounting officer.
- Miller's base salary increased to $300k (from $250k) and bonus target raised to 30% (from 25%).
- Company initiates search for a permanent CFO.

## SEC filing metadata
- accession: 0001193125-21-297901
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2021-10-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000119312521297901/0001193125-21-297901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000119312521297901/d230267d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-297901
- JSON: https://secwatch.observer/filing/0001193125-21-297901.json
- Plain text: https://secwatch.observer/filing/0001193125-21-297901.txt

## Key facts
- Executive change
  Clinton Musil resigned as Chief Financial Officer at GYRE THERAPEUTICS, INC..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On October 7, 2021, Clinton Musil, Chief Financial Officer of Catalyst Biosciences, Inc. (the “Company”), notified the Company of his decision to resign for personal reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000119312521297901/0001193125-21-297901-index.htm
- Executive change
  Seline Miller changed role as Senior Vice President, Finance and interim Chief Financial Officer at GYRE THERAPEUTICS, INC..
  - Action: promoted
  - Role: Senior Vice President, Finance and interim Chief Financial Officer
  source text: Seline Miller, the Company’s Controller, was promoted to Senior Vice President, Finance and will serve as the Company’s interim Chief Financial Officer and interim Principal Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000119312521297901/0001193125-21-297901-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.